title: Treatment of severe osteoporosis with alendronate in a patient with lysinuric protein intolerance.
abstract: Lysinuric protein intolerance is an inborn error of cationic amino acid transport of which osteoporosis is a major feature. Treatment with oral bisphosphonates improves bone mineral density even in severe osteoporosis.
authors.affiliation: Unidad de Enfermedades Metabólicas, Hospital Sant Joan de Déu, Barcelona, Spain. lgomez@hsjdbcn.org
authors.forename: L
authors.initials: L
authors.lastname: Gömez
authors.forename: A
authors.initials: A
authors.lastname: García-Cazorla
authors.forename: A
authors.initials: A
authors.lastname: Gutiérrez
authors.forename: R
authors.initials: R
authors.lastname: Artuch
authors.forename: V
authors.initials: V
authors.lastname: Varea
authors.forename: J
authors.initials: J
authors.lastname: Martín
authors.forename: S
authors.initials: S
authors.lastname: Pinillos
authors.forename: M A
authors.initials: MA
authors.lastname: Vilaseca
mesh_terms: D019386:Alendronate / Q000494:pharmacology*; D000592:Amino Acid Metabolism, Inborn Errors / Q000150:complications* / Q000628:therapy*; D050071:Bone Density Conservation Agents / Q000494:pharmacology; D006801:Humans; D008239:Lysine / Q000737:chemistry*; D010024:Osteoporosis / Q000150:complications* / Q000628:therapy*
chemical_list: D050071:Bone Density Conservation Agents; D008239:Lysine; D019386:Alendronate